Descriptive plasma kinetics of EPA and DHA after administration of a single oral dose of their lysine salts, compared to that after an oral dose of a fish-oil food supplement

Descriptive plasma kinetics of EPA and DHA after administration of a single oral dose of their lysine salts, compared to that after an oral dose of a fish-oil food supplement - Relative oral bio-availability of omega-3 fatty acid lysine salts

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

NL-OMON

Registry ID

NL-OMON46658

Enrollment

Registered

2018-05-28

Start date

2018-06-19

Completion date

Unknown

Last updated

2024-04-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

voedingsonderzoek n.a. healthy individuals

Interventions

Orale dose of EPA en DHA lysine salts or vis oil food supplementen (containing EPA en DHA).

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: * BMI between 18.5 and 25 kg/m2 * Age is between 18 and 28 years * Good general health * Female * Veins suitable for blood sampling

Exclusion criteria

Exclusion criteria: * Current diseases * Any gastrointestinal conditions/diseases within the 3 months prior to the intervention * Haemoglobin (Hb) level 2 kg in the month prior to the intervention * Use of omega-3 or fish oil supplements, 3 weeks before-, or during the intervention. * Not willing to eat fish oil products or animal products * Allergies to (shell)fish or soy products. * Allergies to gluten or milk product. * Following a certain diet * (History of) drug abuse, in this case meaning >1 x per month use of recreational drugs * Smoking * Alcohol consumption of >10 standardised glasses per week. * Recent or planned blood donation (

Design outcomes

Primary

Measure	Time frame
The main study and evaluate parameter is the plasma-time curve of free and esterified EPa and DHA. This will be studied using descriptive kinetics (maximum peak height (Cmax), time-to-peak (Tmax), and area-under-the-curve (AUC)).	—

Secondary

Measure	Time frame
The secondary study parameter is the plasma-time curve of satiety hormones GLP-1, PYY and CCK.	—

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)